Compania de Minas Buenaventura SA (NYSE:BVN), Peru's largest publicly traded, precious metals mining company, announced that it has filed its 2010 20-F with the SEC. The document can be accessed by visiting either the SEC's website at www.sec.gov, or the Company's website at: www.buenaventura.com.pe.
Compania de Minas Buenaventura S.A.A., a precious metals company, engages in the exploration, mining, processing, and development of gold, silver, and other metals in Peru. It also explores for zinc, lead, and copper.
Power3 Medical Products, Inc. (PWRM.OB)
Power3 Medical is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.
Breast cancer or 'breast carcinoma' is the most common form of cancer and the second leading cause of death in women. This occurs when the abnormal cells multiply and go out of control. It begins with the formation of a tumor. If the tumor is malignant, it has the potential to grow and spread or metastasize to different parts of the body through the blood stream or the lymphatic system.
Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.
BC-SeraPro™ test by Power3 Medical is proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
For more information, please visit the website: http://www.power3medical.com
Waddell & Reed Financial Inc. (NYSE:WDR) the Board of Directors of Waddell & Reed Financial, Inc. (NYSE:WDR) approved a quarterly dividend on its Class A common stock to $0.20 per share payable on August 1, 2011 to stockholders of record as of July 8, 2011. Waddell & Reed Financial, Inc. will announce second quarter 2011 earnings before trading begins on the New York Stock Exchange, Tuesday, July 26, 2011. Henry J. Herrmann, chief executive officer, will host a conference call on July 26th at 10:00 a.m. Eastern. To listen to this call live on the internet, visit website at www.waddell.com. A replay will be made available shortly after the conclusion of the call and accessible for seven days.
Waddell & Reed Financial, Inc., through its subsidiaries, provides investment management, investment product underwriting and distribution, and shareholder services administration to mutual funds, and institutional and separately managed accounts in the United States.
Gildan Activewear Inc. (NYSE:GIL) announced that it has increased its existing unsecured revolving bank credit facility to US$800 million from US$400 million and has extended the maturity date to June 2016 from June 2013. As previously disclosed, the Company utilized approximately US$250 million of its bank facility to finance its acquisition of Gold Toe Moretz Holdings Corp. in April 2011. The increase in the amount of the facility is intended to provide the Company with continuing financing flexibility, primarily to be able to respond to potential future acquisition opportunities which complement its organic growth strategy.
Gildan Activewear Inc. manufactures and sells T-shirts, activewear, underwear, and socks to wholesale screen printers, embroiderers, and retailers in North America, Europe, and internationally.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).